By leveraging cutting-edge bioengineering and molecular technologies, we are on a quest to develop a breakthrough Universal Cancer Vaccine. Similar to the way COVID-19 vaccines train the body to recognize and destroy the coronavirus, we are developing a universal cancer vaccine that uses the body’s immune system to detect, mark and destroy cancer cells.
As we search for a universal cancer vaccine, we are also developing conventional immunotherapy treatments. One program, performed at the Jonsson Comprehensive Cancer Center, is targeted at treating Ewing Sarcoma, a rare but deadly bone and soft tissue cancer that primarily affects children and young adults. There is currently no FDA approved treatment for recurrence. We intend to become a dominant player in the immunotherapy space by partnering with leading researchers and institutions to develop a robust portfolio of cancer vaccines. We look forward to the day when treating cancer will be as simple as getting a flu shot.
Cancer vaccines can train the body to target and destroy specific cancer cells. Cancer vaccines are also known as immunotherapy.
Much like the COVID-19 vaccines that train the body to recognize and destroy the coronavirus, cancer vaccines can train the body to target and destroy specific cancer cells.
By leveraging cutting-edge bioengineering and molecular technologies, we developing a breakthrough Universal Cancer Vaccine (UCV).
The UCV will force cancer cells to express a non-naturally occurring protein marker that can be used by the immune system and custom antibodies to precisely target cancer cells for destruction.
We have entered into a sponsored research agreement (SRA) with the University of California at Los Angeles (UCLA) to help us develop this Universal Cancer Vaccine platform. We hold exclusive rights to license all intellectual property and related technology produced through our partnership with UCLA.
We are developing a disease-specific immunotherapy targeted at treating Ewing Sarcoma, a rare but deadly bone and soft tissue cancer that affects children and young adults.
We have entered into a sponsored research agreement (SRA) with the University of California at Los Angeles (UCLA), lead by a team of professors and physicians who run the Ewing Sarcoma Program at the UCLA Jonsson Comprehensive Cancer Center.
Ryan has had a successful career as an entrepreneur, business executive and public servant. Prior to joining CancerVAX, Ryan co-founded several biotech companies/technologies including a nitric oxide topical wound-care product, a medical device company (drug delivery system) and an antibiotic drug development company. Ryan served as CEO of Curza, a small molecule therapeutics company focused on developing new antibiotics; SVP at Clarke Capital Partners, a private growth equity investment firm; co-founder of a software/ecommerce company Found.com (acquired by CRS Retail Systems); co-founder of a software company O2 Blue (acquired by Prebon Yamane). His public service activities include serving on the Draper, Utah City Council and serving on the campaigns of two U.S. presidential candidates, one U.S. senate candidate and two gubernatorial candidates. Ryan holds degrees in Business Management from Ricks College and Political Science from Brigham Young University.
Dr. Jonas is a UCLA physician-scientist specializing in pediatric hematology/oncology. He received a bachelor’s degree in materials science & engineering and a master’s degree in biomedical engineering prior to starting his medical training to pursue his M.D. and Ph.D. degrees at UCLA through its NIH-supported Medical Scientist Training Program. He leads a multidisciplinary research team that targets the development and application of new nanotechnologies and methods to support the childhood cancer and regenerative medicine communities in accelerating the discovery of innovative gene therapy approaches.
Dr. De Oliveira is a board-certified pediatrician and board-certified pediatric hematology/oncologist. He received his medical degree in Brazil and completed his pediatric residency at Woodhull Medical and Mental Health Center in New York and his pediatric hematology/oncology fellowship at the Children’s Hospital Lost Angeles. His clinical focus is on pediatric oncology and gene therapies and his research focus is on cancer immunotherapy and biology of stem cell transplantation.
Dr. Seet is a hematologist and oncologist subspecializing in the treatment of hematologic malignancies, including hematopoietic stem cell transplantation, cellular therapy and clinical trials of novel therapeutics. He received a undergraduate degree in Biological Science at the University of Chicago, a medical degree at the University of Sydney, Australia and PhD in Cellular and Molecular Pathology at UCLA. His research focuses on human T cell and dendritic cell tumor immunology, and the development of engineered stem cell-based approaches to cancer therapy.
Dr. Federman is the Director of the Pediatric Bone and Soft Tissue Sarcoma Program at UCLA. He specializes in treating children, adolescents and young adults with these aggressive cancers. He runs a multidisciplinary program involving pediatric and medical oncologists, radiation oncologists, orthopedic oncology surgeons, musculoskeletal radiologists and pathologists, nuclear medicine specialists, physical therapists and prosthetic specialists. He received a medical degree from the Icahn School of Medicine at Mount Sinai and completed his residency and fellowship at UCLA.
Dr. Denny has served as a physician at UCLA for over 3 decades primarily focused on pediatric oncology. He has trained and mentored some of UCLA’s best and brightest scientists and doctors in the field. Dr. Denny received a bachelor’s degree from University of Pennsylvania and a medical degree from the University of Pennsylvania School of Medicine. He completed his residency at the Children’s National Medical Center and fellowship at the National Institutes of Health Clinical Center. Most of Dr. Denny’s academic success has come through applying basic molecular biology tools to seek molecular mechanisms for what he witnesses when treating pediatric hematology/oncology patients.
Years of collective